利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.038 秒)

    Open chain prolyl urea-related modulators of androgen receptor function
    1.
    发明授权
    Open chain prolyl urea-related modulators of androgen receptor function 有权
    开链脯氨酰脲相关调节剂的雄激素受体功能

    公开(公告)号：US07632858B2

    公开(公告)日：2009-12-15

    申请号：US10712456

    申请日：2003-11-13

    申请人： Lawrence G. Hamann ,  David J. Augeri ,  Mark C. Manfredi

    发明人： Lawrence G. Hamann ,  David J. Augeri ,  Mark C. Manfredi

    IPC分类号： C07D207/12 ,  A61K31/4015 ,  A61P35/00

    CPC分类号： C07D207/16 ,  C07D401/12

    摘要： The invention provides for a pharmaceutical composition capable of modulating the androgen receptor comprising a compound of formula I wherein R1, R2, R3, X, Y, Z and G are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.

    摘要翻译： 本发明提供能够调节包含式I化合物的雄激素受体的药物组合物，其中R 1，R 2，R 3，X，Y，Z和G如本文所述。 还提供了使用这些化合物治疗核激素受体相关病症（如与年龄相关的疾病，例如肌肉减少症）的方法，并且还提供含有这些化合物的药物组合物。

    Sulfonylpyrrolidine modulators of androgen receptor function and method
    2.
    发明授权
    Sulfonylpyrrolidine modulators of androgen receptor function and method 有权
    磺酰吡咯烷酮调节剂的雄激素受体功能及方法

    公开(公告)号：US07989640B2

    公开(公告)日：2011-08-02

    申请号：US12880692

    申请日：2010-09-13

    申请人： Lawrence G. Hamann ,  Yingzhi Bi ,  Mark C. Manfredi ,  Alexandra A. Nirschl ,  James C. Sutton

    发明人： Lawrence G. Hamann ,  Yingzhi Bi ,  Mark C. Manfredi ,  Alexandra A. Nirschl ,  James C. Sutton

    IPC分类号： C07D207/00

    CPC分类号： C07D285/14 ,  C07D207/48

    摘要： Compounds are provided which are useful in the treatment of androgen receptor-associated conditions, such as age-related diseases, which compounds have the structure wherein R1, R2 and R4, are as defined herein; G is an aryl, heterocyclo or heteroaryl group, wherein said group is mono- or polycyclic, and which is optionally substituted; n is an integer of 1 or 2; m is an integer of 1 or 2; Z is oxygen (—O—) or NR4h; a prodrug ester, all stereoisomers thereof and a pharmaceutically acceptable salt thereof. A method for treating androgen receptor-associated conditions such as age-related diseases is also provided.

    摘要翻译： 提供了可用于治疗雄激素受体相关病症例如年龄相关疾病的化合物，该化合物具有其中R1，R2和R4如本文所定义的结构; G是芳基，杂环或杂芳基，其中所述基团是单环或多环，并且其任选被取代; n为1或2的整数; m为1或2的整数; Z是氧（-O-）或NR4h; 前药酯，其所有立体异构体和其药学上可接受的盐。 还提供了治疗雄激素受体相关病症如年龄相关疾病的方法。

    Sulfonylpyrrolidine modulators of androgen receptor function and method
    3.
    发明授权
    Sulfonylpyrrolidine modulators of androgen receptor function and method 有权
    磺酰吡咯烷酮调节剂的雄激素受体功能及方法

    公开(公告)号：US07820702B2

    公开(公告)日：2010-10-26

    申请号：US11048439

    申请日：2005-02-01

    申请人： Lawrence G. Hamann ,  Yingzhi Bi ,  Mark C. Manfredi ,  Alexandra A. Nirschl ,  James C. Sutton

    发明人： Lawrence G. Hamann ,  Yingzhi Bi ,  Mark C. Manfredi ,  Alexandra A. Nirschl ,  James C. Sutton

    IPC分类号： A61K31/433 ,  C07D285/10

    CPC分类号： C07D285/14 ,  C07D207/48

    摘要： Compounds are provided which are useful in the treatment of androgen receptor-associated conditions, such as age-related diseases, which compounds have the structure wherein R1, R2, R3, R4, R4a, R4b, R4c, R4c1, Rd, Re, Rf, Rg, Rh, R5, R5′, R7, and R7′ are defined herein; G is aryl, heterocycle or heteroaryl group, wherein said group is mono- or polycyclic, and which is optionally substituted; and n is an integer of 1 or 2, m is an integer of 1 or 2, Z is oxygen (—O—) or NR4b, a prodrug ester, all stereoisomers thereof and a pharmaceutically acceptable salt thereof. A method for treating androgen receptor-associated conditions such as age-related diseases is also provided.

    摘要翻译： 提供了可用于治疗雄激素受体相关病症例如年龄相关疾病的化合物，该化合物具有其中R1，R2，R3，R4，R4a，R4b，R4c，R4c1，Rd，Re，Rf ，R g，Rh，R 5，R 5'，R 7和R 7'如本文所定义; G是芳基，杂环或杂芳基，其中所述基团是单环或多环，并且其任选被取代; n为1或2的整数，m为1或2的整数，Z为氧（-O-）或NR4b，前药酯，其全部立体异构体及其药学上可接受的盐。 还提供了治疗雄激素受体相关病症如年龄相关疾病的方法。

    SULFONYLPYRROLIDINE MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD
    5.
    发明申请
    SULFONYLPYRROLIDINE MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD 有权
    雄激素受体功能和方法的磺酰胆碱调节剂

    公开(公告)号：US20110015408A1

    公开(公告)日：2011-01-20

    申请号：US12880692

    申请日：2010-09-13

    申请人： Lawrence G. Hamann ,  Yingzhi Bi ,  Mark C. Manfredi ,  Alexandra A. Nirschl ,  James C. Sutton

    发明人： Lawrence G. Hamann ,  Yingzhi Bi ,  Mark C. Manfredi ,  Alexandra A. Nirschl ,  James C. Sutton

    IPC分类号： C07D207/48

    CPC分类号： C07D285/14 ,  C07D207/48

    摘要： Compounds are provided which are useful in the treatment of androgen receptor-associated conditions, such as age-related diseases, which compounds have the structure whereinR1, R2 and R4, are as defined herein;G is an aryl, heterocyclo or heteroaryl group, wherein said group is mono- or polycyclic, and which is optionally substituted;n is an integer of 1 or 2;m is an integer of 1 or 2;Z is oxygen (—O—) or NR4h;a prodrug ester, all stereoisomers thereof and a pharmaceutically acceptable salt thereof. A method for treating androgen receptor-associated conditions such as age-related diseases is also provided.

    摘要翻译： 提供了可用于治疗雄激素受体相关病症例如年龄相关疾病的化合物，该化合物具有其中R1，R2和R4如本文所定义的结构; G是芳基，杂环或杂芳基，其中所述基团是单环或多环，并且其任选被取代; n为1或2的整数; m为1或2的整数; Z是氧（-O-）或NR4h; 前药酯，其所有立体异构体和其药学上可接受的盐。 还提供了治疗雄激素受体相关病症如年龄相关疾病的方法。

    Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
    9.
    发明授权
    Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them 有权
    取代的噻吩并[3,2-d]嘧啶酮作为MCHR1拮抗剂及其使用方法

    公开(公告)号：US08618115B2

    公开(公告)日：2013-12-31

    申请号：US11586255

    申请日：2006-10-25

    申请人： William N. Washburn ,  Mark C. Manfredi ,  Jeffrey A. Robl ,  Andres S. Hernandez

    发明人： William N. Washburn ,  Mark C. Manfredi ,  Jeffrey A. Robl ,  Andres S. Hernandez

    IPC分类号： C07D495/04 ,  A61K31/519 ,  A61P3/04 ,  A61P3/10 ,  A61P25/22 ,  A61P25/24

    CPC分类号： C07D495/04

    摘要： The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

    摘要翻译： 本申请提供化合物，包括根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式。另外，本申请提供含有至少一种根据式I的化合物和任选的至少一种另外的治疗剂的药物组合物。 最后，本申请提供了通过施用治疗有效剂量的根据式I的化合物治疗患有MCHR-1调节的疾病或病症例如肥胖，糖尿病，抑郁或焦虑的患者的方法。